Pharmaceuticals

How Is The ACE Inhibitors Market Expected To Grow At 6.2% CAGR Over 2025–2029?

September 23, 2025 by Marketing Posting

Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

#How Will The ACE Inhibitors Market Valuation Change Between Now And 2029?#_x000D_

Over the past few years, the market for ACE inhibitors has seen steady growth. The prediction indicates a growth from $7.15 billion in 2024 reaching $7.41 billion in 2025, boasting a compound annual growth rate (CAGR) of 3.6%. Factors like increased instances of cardiovascular diseases, an uptick in the elderly population, clinical efficacy and safety, prevalence of diabetes, along with regulatory approvals and guidelines have contributed to this historical growth rate._x000D_

_x000D_

The market for ACE inhibitors is forecasted to experience significant expansion in the coming years, with projections placing it at $9.42 billion in 2029, boasting a compound annual growth rate (CAGR) of 6.2%. This pronounced growth for the forecasted period can be linked to the increasing global prevalence of cardiovascular diseases, the extension of treatment guidelines for hypertension, the advent of advanced combination therapies, an emphasis on managing heart failure, and improved awareness and access to healthcare. Key market trends in the forecast period encompass an enhanced focus on kidney protection, a preference for renin-angiotensin system inhibitors, competitive pressures from generics and pricing, a more patient-focused approach in healthcare, as well as regulatory changes and considerations related to safety._x000D_

_x000D_

#Get A Free Sample Of The Report:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=10671&type=smp_x000D_

_x000D_

#Which Industry Forces Are Driving The ACE Inhibitors Market Forward?#_x000D_

The continuous rise in hypertension disorders is anticipated to fuel the expansion of the ACE inhibitors market. Hypertension, colloquially referred to as high blood pressure, is typified by an increased pressure in the blood vessels. ACE inhibitors, also known as angiotensin-converting enzyme inhibitors, are crucial medications used to manage and control hypertension. These drugs work by easing up the blood vessels, which reduces blood pressure and enhances blood flow. For example, in March 2023, as per the records of the World Health Organization, a dedicated agency of the United Nations based in Switzerland, around 1.28 billion adults aged between 30 and 79 suffered from hypertension globally, with two-thirds predominantly residing in developing countries. Over the past 30 years, an additional 650 million adults between 30 and 79 years old have been impacted by high blood pressure. It is estimated that nearly 46% of adults stricken with hypertension remain undiagnosed and thus, are unaware of their health condition. The figure has alarmingly surged by 650 million in the past three decades. Consequently, the ever-increasing prevalence of hypertension disorders is a significant factor propelling growth in the ACE inhibitors market._x000D_

_x000D_

#Which Segmentation Categories Are Highlighted In The ACE Inhibitors Market Analysis?#_x000D_

The ace inhibitors market covered in this report is segmented – _x000D_

_x000D_

1) By Type: Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents_x000D_

2) By Drug: Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Other Drugs_x000D_

3) By Dosage Form: Oral Tablets, Oral Solutions_x000D_

4) By Application: Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Other Applications_x000D_

5) By End-Users: Hospitals, Online Drug Stores, Other End-Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Sulfhydryl-Containing Agents: Captopril, Zofenopril_x000D_

2) By Dicarboxylate-Containing Agents: Enalapril, Lisinopril, Ramipril, Quinapril, Benazepril, Perindopril_x000D_

3) By Phosphonate-Containing Agents: Fosinopril_x000D_

_x000D_

#Which Market Trends Are Expected To Define The Future Of The ACE Inhibitors Market?#_x000D_

Trend 1: The ACE inhibitors market is witnessing a rise in product innovations as a key trend. The primary focus of leading companies in the ACE inhibitors market is on the creation of pioneering products to consolidate their market standing and carve out a competitive edge. For illustration, in February 2023, Travere Therapeutics, a biopharmaceutical organization hailing from the United States, procured FDA recognition for FILSPARI (sparsentan), a unique non-immunosuppressive therapy for IgA nephropathy (IgAN) patients. The therapy regimes encompass systemic glucocorticoids, angiotensin-converting enzyme (ACE) inhibitors, and medications for hypertension, inclusive of angiotensin-receptor blockers (ARBs). FILSPARI represents the single non-immunosuppressive therapy to receive approval, and it is a once-daily oral medication aimed at treating adults suffering from primary IgAN with a high risk of rapid disease progression and who typically have a UPCR lower than 1.5 g/g along with proteinuria._x000D_

_x000D_

#Which Players Are Shaping The Competitive Landscape Of The ACE Inhibitors Market?#_x000D_

Major companies operating in the ACE inhibitors market include Pfizer Inc., Novartis AG, Johnson & Johnson Private Limited, Merck KGaA, Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Co., Takeda Pharmaceuticals Company, Daiichi Sankyo Company Ltd., UCB Schwarz Pharma Inc., Endo International plc, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, Bausch Health Companies Inc., Dr. Reddy’s Laboratories, Abbott Laboratories, Eli Lilly and Company, Cipla Limited, GlaxoSmithKline plc, Cadila Healthcare Limited, AbbVie Inc., Sandoz Group AG, Accord Healthcare Ltd., AstraZeneca plc, Lupin Limited, Macleods Pharmaceuticals Limited, Zydus lifescience Ltd., Apotex Inc. _x000D_

_x000D_

#Access The Complete Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report_x000D_

_x000D_

#Which Regional Markets Are Emerging As Key Hubs For The ACE Inhibitors Market?#_x000D_

North America was the largest region in the ACE inhibitors market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in the ace inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

_x000D_

#Customize Your Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=10671&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_